Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 9/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 2/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.34 |
| ▸ | GLRB | P48167 | 1/20 | 0.34 |
| ▸ | GRN | P28799 | 1/20 | 0.34 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1044787 | 0.79 | NOTUM (0.41) | MEN1KMT2ANOTUMKDM4EGAA | |
| SCHEMBL6622235 | 0.75 | NOTUM (0.39) | MEN1KMT2ANOTUMKDM4EGAA | |
| SCHEMBL13315133 | 0.74 | ALDH1A1 (0.43) | MEN1KMT2AHPGD | |
| SCHEMBL4472003 | 0.72 | ALOX15 (0.48) | KDM4EGAAHPGDHSD17B10 | |
| SCHEMBL16418933 | 0.72 | NOTUM (0.70) | MEN1KMT2ANOTUMKDM4EGAA | |
| SCHEMBL14157647 | 0.71 | GPR35 (0.41) | MEN1KMT2ANOTUMKDM4EGAA | |
| SCHEMBL7623372 | 0.69 | KDM4E (0.34) | NOTUMKDM4EGAAHPGDHSD17B10 | |
| SCHEMBL4470824 | 0.68 | HCAR2 (0.41) | MEN1KMT2ANOTUMKDM4EGAA | |
| SCHEMBL4011812 | 0.67 | DAO (0.32) | KDM4EGAAHPGD | |
| SCHEMBL23923900 | 0.67 | GAA (0.39) | MEN1KMT2ANOTUMKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178780-A1 | RAF KINASE INHIBITORS | WOOD JILL E (US) | 2012-07-12 | — | — | US | disclosed |
| US-7741479-B2 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20100063088-A1 | Raf Kinase Inhibitors | WOOD JILL E | 2010-03-11 | — | — | US | disclosed |
| EP-0986382-B1 | RAF KINASE INHIBITORS | BAYER PHARMACEUTICALS CORP (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20050256174-A1 | Raf kinase inhibitors | BAYER HEALTHCARE LLC | 2005-11-17 | — | — | US | disclosed |
| US-20010006975-A1 | Raf kinase inhibitors | BAYER CORPORATION AND ONYX PHARMACEUTICALS WEST HAVEN, CT AND RICHMOND, CA, RESPECTIVELY | 2001-07-05 | — | — | US | disclosed |
| EP-0986382-A4 | RAF KINASE INHIBITORS | BAYER AG (US) | 2001-04-11 | — | — | EP | disclosed |
| US-6187799-B1 | TREATING CANCEROUS CELL GROWTH MEDIATED BY RAF KINASE BY ADMINISTERING SPECIFIED COMPOUNDS, SUCH AS 2-(METHYOXYCARBONYL),3-((4-METHYLPHENYL)UREA),5-ALKYL-THIOPHENE | ONYX PHARMACEUTICALS | 2001-02-13 | — | — | US | disclosed |
| EP-0986382-A1 | RAF KINASE INHIBITORS | Bayer Corporation (US) | 2000-03-22 | — | — | EP | disclosed |
| WO-1998052559-A1 | RAF KINASE INHIBITORS | BAYER CORPORATION (US) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063088-A1 | Raf Kinase Inhibitors | BRAF, RAF1, ARAF | MAPK14 239/4885MEN1 2219/4885KMT2A 1990/4885 |
| US-20050256174-A1 | Raf kinase inhibitors | BRAF, RAF1, ARAF | MAPK14 239/4885MEN1 2219/4885KMT2A 1990/4885 |
| US-20120178780-A1 | RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | MAPK14 239/4885MEN1 2219/4885KMT2A 1990/4885 |
| US-20010006975-A1 | Raf kinase inhibitors | BRAF, RAF1, ARAF | MAPK14 239/4885MEN1 2219/4885KMT2A 1990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.